Zentalis Pharmaceuticals (ZNTL) Total Non-Current Liabilities (2019 - 2026)

Zentalis Pharmaceuticals' Total Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $69.9 million for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities fell 20.66% year-over-year to $69.9 million in Q1 2026; TTM through Mar 2026 was $69.9 million, a 20.66% decrease from a year earlier, with the FY2025 full-year figure at $72.3 million, down 21.71% from the prior year.
• Total Non-Current Liabilities declined to $69.9 million in Q1 2026 per ZNTL's latest filing, from $72.3 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $112.5 million in Q4 2023 and bottomed at $45.0 million in Q1 2022.
• The 5-year median for Total Non-Current Liabilities is $95.3 million (2024), against an average of $90.1 million.
• Across the five-year window, Total Non-Current Liabilities jumped 163.56% in 2022 and dropped 28.98% in 2025, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $102.7 million in 2022, then gained by 9.6% to $112.5 million in 2023, then declined by 17.97% to $92.3 million in 2024, then fell by 21.71% to $72.3 million in 2025, then fell by 3.29% to $69.9 million in 2026.
• Per Business Quant, the three latest ZNTL Total Non-Current Liabilities figures stand at $69.9 million (Q1 2026), $72.3 million (Q4 2025), and $73.9 million (Q3 2025).